SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics (SWTX) announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult patients with progressing desmoid tumors who require systemic treatment.The company also outlined some expected milestones related to its commercial portfolio and other pipeline candidates for 2025.Shares of SWTX were down 13.9% on Jan. 13 following the news announcement.In the past year, shares of SpringW ...